Manufacturer
Mylan Laboratories Limited
Contents
Pamidronate disodium
Indication
Conditions associated w/ increased osteoclast activity eg, predominantly lytic bone metastases from breast cancer & advanced multiple myeloma. Acute management of tumour-induced hypercalcemia. Symptomatic treatment of Paget's bone disease.
Instruction
Administer via IV infusion
Drug interaction
Significant hypocalcaemia w/ other bisphosphonates. Synergistic effect w/ calcitonin. Increased risk of renal dysfunction in combination w/ thalidomide. Concomitant use w/ potentially nephrotoxic drugs.
Malaysia
